摘要
目的探讨恩度联合FOLFOX4方案治疗晚期结直肠癌的临床疗效及对患者T淋巴细胞亚群的影响。方法入组我院2010年1月至2017年12月收治的晚期结直肠癌患者200例,采用随机数字表法分为对照组和观察组,每组100例。观察组采用恩度联合FOLFOX4方案化疗,对照组采用XELOX方案化疗。比较2组治疗前后T淋巴细胞亚群变化、临床疗效及不良反应。结果2组治疗前T淋巴细胞亚群指标比较差异均无统计学意义(P均>0.05);治疗后,2组CD3+比较差异均无统计学意义(P>0.05),而CD4+及CD4+/CD8+均升高,CD8+均降低(P<0.05);观察组治疗后CD4+及CD4+/CD8+均高于对照组,CD8+低于对照组(P<0.05)。观察组疾病控制率为80.00%(80/100),明显高于对照组的64.00%(64/100,P<0.05)。2组各不良反应发生率比较差异均无统计学意义(P均>0.05)。结论恩度联合FOLFOX4方案治疗可提高晚期结直肠癌患者的临床疗效,改善患者免疫功能,患者耐受性好,且不良反应低,可进行临床推广应用。
Objective To investigate the clinical effect of endostar plus FOLFOX4 chemotherapy in the treatment of patients with advanced colorectal cancer and its influence on T lymphocyte subsets.Methods The 200 patients with advanced colorectal cancer admitted to our hospital from January 2010 to December 2017 were selected as the research subjects.They were divided into the control group and the observation group by using random number table grouping method,100 patients in each group.The observation group was treated with Endostar combined with FOLFOX4 regimen chemotherapy,while the control group was treated with XELOX regimen chemotherapy.The changes of T lymphocyte subsets,clinical efficacy and toxicities were compared between the two groups before and after treatment.Results There was no significant difference in T lymphocyte subsets between the two groups before treatment(P>0.05).After treatment,the levels of CD3+,CD4+,CD4+/CD8+increased,and CD8+decreased in the two groups(P<0.05).After treatment,the levels of CD4+and CD4+/CD8+in the observation group were higher than those in the control group,and CD8+was lower than that in the control group(P<0.05).The control rate of the observation group[80.00%(80/100)]was higher than that of the control group[64.00%(64/100),P<0.05].There was no significant difference in clinical toxicities between the two groups(P>0.05).Conclusion Endostar combined with FOLFOX4 regimen can improve the clinical efficacy and immune function of patients with advanced colorectal cancer,endostar combined with FOLFOX4 regimen has good tolerance and low toxicity.
作者
王超
曹爱玲
乐玲
WANG Chao;CAO Ailing;LE Ling(Department of Oncology,the First Affiliated Hospital of Hubei Institute of Science and Technology,Xianning 437100,China)
出处
《肿瘤基础与临床》
2019年第5期385-388,共4页
journal of basic and clinical oncology
作者简介
王超(1981-),男,硕士,主治医师,主要从事恶性肿瘤的诊断与治疗工作。E-mail:1016942941@qq.com;通信作者:曹爱玲(1968-),女,副主任医师,主要从事恶性肿瘤的诊断与治疗工作。E-mail:2446817776@qq.com。
